Original research
Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address